A drug-resistant fungal infection that kills up to 60% of those it infects has now spread to more than 60 countries across six continents — and health authorities warn the worst may be ahead.
Candida auris, a multidrug-resistant yeast first identified in a Japanese patient's ear canal in 2009, has become one of the most urgent antimicrobial resistance threats of the decade. The World Health Organization has placed it in the "Critical Priority" category of its Fungal Priority Pathogens List, while the U.S. Centers for Disease Control and Prevention classifies it as an "Urgent Threat" — its highest level of concern.
- **60+ countries** affected across six continents
- **7,000+ clinical cases** reported in the U.S. in 2025 alone
- **30–60% mortality** rate in severely ill patients
- **95% of U.S. isolates** resistant to fluconazole, the most common antifungal
- Survives on hospital surfaces for **weeks**, resisting standard disinfectants
The Numbers Tell the Story
The trajectory of C. auris in the United States illustrates how quickly a stealth pathogen can establish itself. From just 51 clinical cases in 2016, infections have exploded — reaching 4,514 in 2023, 6,304 in 2024, and surpassing 7,000 across 27 states by early 2026.
California and Nevada alone account for over 40% of U.S. cases in 2025. But the geographic footprint keeps expanding — from zero affected states in 2015 to more than half the country today.
In Europe, the picture is equally alarming. A September 2025 survey by the European Centre for Disease Prevention and Control confirmed rapid hospital-level spread, with 1,346 cases reported across 18 EU countries in 2023 alone. Spain, Greece, Italy, and Romania have seen such widespread dissemination that they can no longer distinguish individual outbreaks from endemic transmission.
Why This Fungus Is Different
Most fungal infections don't make headlines. C. auris does — for three reasons that set it apart from virtually every other pathogen in its class.
It resists nearly everything. A February 2026 CDC study analyzing U.S. isolates found staggering resistance rates:
| Antifungal Class | Drug Example | Resistance Rate | Clinical Impact |
|---|---|---|---|
| Azoles | Fluconazole | 95% | First-line treatment rendered useless |
| Polyenes | Amphotericin B | 15% | Backup option increasingly unreliable |
| Echinocandins | Caspofungin | 1% | Current best option, but resistance growing |
| All three classes | Pan-resistant | <1% | Essentially untreatable cases emerging |
It lives on surfaces. Unlike most yeasts, C. auris can survive on hospital bedrails, sinks, and medical equipment for weeks. Standard cleaning products often fail to eliminate it, turning healthcare facilities into reservoirs for transmission.
It hides. Standard laboratory tests frequently misidentify C. auris as other Candida species — particularly C. haemulonii — leading to delayed diagnosis and incorrect treatment. By the time clinicians realize what they're dealing with, the infection has often progressed.
A Climate Change Connection?
One of the most provocative hypotheses about C. auris links its emergence to rising global temperatures. Most fungi cannot survive at human body temperature — our internal heat acts as a natural "thermal barrier" against fungal invasion. Some researchers believe C. auris adapted to higher ambient environmental temperatures, effectively training itself to tolerate the human body's defenses.
KEY STAT: C. auris was first retrospectively identified from a 1996 sample in South Korea — but wasn't recognized as a distinct species until 2009. It may have been spreading undetected for over a decade.
Dr. Anuradha Chowdhary of the University of Delhi's Medical Mycology Unit has published research supporting this theory, suggesting that agricultural fungicide use and warming climates may have created the evolutionary pressure that produced this superbug.
Timeline: From Discovery to Global Emergency
What's Being Done
The response is accelerating, but experts warn it may not be fast enough.
New treatments are arriving. The FDA-approved drug rezafungin (Rezzayo), a once-weekly echinocandin, is being deployed as a front-line option. Researchers have also reported promising results combining caspofungin and posaconazole against C. auris biofilms — the sticky microbial communities that make the fungus so difficult to eradicate from hospital environments.
Screening is expanding. More hospitals are implementing admission screening for patients transferred from high-risk facilities or regions where C. auris is endemic. Ontario's decision to make the fungus a reportable disease in January 2026 signals a broader trend toward mandatory surveillance.
But the economics are daunting. The World Bank projects that antimicrobial resistance — the broader category that includes drug-resistant fungi — will add $1 trillion in additional healthcare costs by 2050. Developing new antifungal drugs is expensive and slow, and the pharmaceutical industry has historically underinvested in antifungals compared to antibacterials.
What You Need to Know
For the general public, the immediate risk remains low. C. auris primarily threatens hospitalized patients with serious underlying conditions, invasive medical devices, or compromised immune systems.
But Dr. Hanan Balkhy, WHO Assistant Director-General for Antimicrobial Resistance, has warned that fungal infections are "emerging from the shadows" of the bacterial resistance crisis. The CDC's Dr. Meghan Lyman has called the "rapid rise and geographic spread" alarming, emphasizing the need for expanded laboratory capacity and strict infection prevention protocols.
The message from global health authorities is clear: C. auris is not a future threat. It's a present one — and the window for containment is narrowing.
Sources: CDC Emerging Infectious Diseases (Feb 2026), WHO Fungal Priority Pathogens List, ECDC Surveillance Report (Sep 2025), CIDRAP (Feb 2026), Kurdistan24 (Jan 2026).
